Chemcon Speciality Chemicals Ltd Q1 FY26 – Pharma Intermediates on Life Support, Oilfield Chemicals in ICU
1. At a Glance
Chemcon Speciality Chemicals isn’t your neighborhood masala shop—it’s India’s only HMDS maker and the world’s biggest CMIC factory. Fancy credentials, but the financials look like a patient hooked to oxygen: ROE just 5%, sales growth negative for 5 years, and the stock still trades at 37x earnings. A true case of “exclusive products, inclusive underperformance.”
2. Introduction
Welcome to the curious case of Chemcon: a company that manufactures some of the most mission-critical chemicals for pharma giants, yet struggles to generate mission-critical profits for its shareholders.
Think of it as that one bright kid in class who invented his own chemistry set, became famous for it, but still failed math every year. Chemcon boasts monopoly status in HMDS (used for antivirals) and CMIC (another pharma darling). They’re also the only ones making Zinc Bromide in India. Inorganic, organic, silanes—you name it, they have a factory for it in Vadodara.
And yet, look at the numbers. Sales in FY25: ₹215 Cr. Net profit: ₹25 Cr. ROE: 5%. That’s less than what your neighborhood kirana shop earns on Maggi packets. Stock has given -16% returns in 3 years, but bounced 50% in last 6 months because—well, retail loves anything that “sounds like chemicals.”
Question: If you’re the only maker of HMDS in India and still not making fat margins, should you blame the market… or your management?
3. Business Model – WTF Do They Even Do?
Detective’s notes:
Organic Chemicals (74% revenue)
HMDS → reagent in pharma synthesis.
CMIC → intermediate for antiviral drugs.
Bromobenzene + the new entrant 2-Bromo (FY25). End market = pharma, agro.
Exports = 37% (USA, Italy, South Korea, Germany, etc.). Domestic = 63%. Top 5 customers contribute 40% of revenue—so no one sugar daddy, but still concentrated.
Here’s the paradox: Chemcon makes chemicals without which antivirals and drilling rigs can’t survive. But its own P&L looks like it needs life support.
Commentary: Sales are crawling, profits are inching, valuation is sprinting. Classic case of the stock market saying: “Beta, teri kahani sun ke dil khush hua, lekin paisa toh nahin bana.”
